Abstract
In 25 patients an [14C]-aminopyrine breath test (ABT) was performed immediately before the oral administration of 1.5-2 g of mebendazole three times daily. The concentration of mebendazole in serum was measured 2 h after each drug intake. A significant correlation was found between the results of ABT and the serum drug concentrations obtained after the second and third intake, as well as the highest concentration value. The ABT was repeated in six patients during a continuous treatment with mebendazole. In all of them this test indicated an increase in 14CO2 production with continued treatment. The results support the view that mebendazole is metabolized by the liver monooxygenase activity and behaves as an enzyme inducer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bekhti A. Mebendazole in toxocariasis. Ann Intern Med. 1984 Mar;100(3):463–463. doi: 10.7326/0003-4819-100-3-463_3. [DOI] [PubMed] [Google Scholar]
- Braithwaite P. A., Allan R. J., Dawson M., Roberts M. S., Watson T. R. Cyst and host tissue concentrations of mebendazole in patients undergoing surgery for hydatid disease. Med J Aust. 1983 Oct 15;2(8):383–384. doi: 10.5694/j.1326-5377.1983.tb122534.x. [DOI] [PubMed] [Google Scholar]
- Braithwaite P. A., Roberts M. S., Allan R. J., Watson T. R. Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. Eur J Clin Pharmacol. 1982;22(2):161–169. doi: 10.1007/BF00542462. [DOI] [PubMed] [Google Scholar]
- Bryceson A. D., Woestenborghs R., Michiels M., van den Bossche H. Bioavailability and tolerability of mebendazole in patients with inoperable hydatid disease. Trans R Soc Trop Med Hyg. 1982;76(4):563–564. doi: 10.1016/0035-9203(82)90163-8. [DOI] [PubMed] [Google Scholar]
- Hepner G. W., Vesell E. S. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med. 1975 Nov;83(5):632–638. doi: 10.7326/0003-4819-83-5-632. [DOI] [PubMed] [Google Scholar]
- Michiels M., Hendriks R., Heykants J., van den Bossche H. The pharmacokinetics of mebendazole and flubendazole in animals and man. Arch Int Pharmacodyn Ther. 1982 Apr;256(2):180–191. [PubMed] [Google Scholar]
- Münst G. J., Karlaganis G., Bircher J. Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results. Eur J Clin Pharmacol. 1980 May;17(5):375–378. doi: 10.1007/BF00558451. [DOI] [PubMed] [Google Scholar]
- Pauwels S., Geubel A. P., Dive C., Beckers C. Breath 14CO2 after intravenous administration of [14C]aminopyrine in liver diseases. Dig Dis Sci. 1982 Jan;27(1):49–56. doi: 10.1007/BF01308121. [DOI] [PubMed] [Google Scholar]
- Schantz P. M., Van den Bossche H., Eckert J. Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Z Parasitenkd. 1982;67(1):5–26. doi: 10.1007/BF00929509. [DOI] [PubMed] [Google Scholar]
- Witassek F., Bircher J. Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level. Eur J Clin Pharmacol. 1983;25(1):85–90. doi: 10.1007/BF00544021. [DOI] [PubMed] [Google Scholar]